Diagnostic Workup for Neonatal Persistent Hypoglycemia
For a neonate with persistent hypoglycemia after documented low glucose, immediately obtain critical sample laboratory studies during the next hypoglycemic episode (glucose <50 mg/dL) before treatment, including serum insulin, C-peptide, cortisol, growth hormone, beta-hydroxybutyrate, free fatty acids, lactate, ammonia, and urine ketones and organic acids.
Initial Laboratory Assessment
The cornerstone of diagnosing persistent neonatal hypoglycemia is obtaining a "critical sample" during documented hypoglycemia 1. This timing is essential because these metabolic markers are only interpretable when glucose is low.
Critical Sample Components:
Blood tests to draw simultaneously:
- Serum insulin and C-peptide (to detect hyperinsulinism - the most common cause of persistent hypoglycemia)
- Cortisol and growth hormone (to evaluate hypopituitarism/adrenal insufficiency)
- Beta-hydroxybutyrate and free fatty acids (inappropriately low levels with hypoglycemia suggest hyperinsulinism; elevated levels suggest fatty acid oxidation defects)
- Lactate (elevated in glycogen storage diseases)
- Ammonia (elevated in certain metabolic disorders)
- Blood gas (to assess for metabolic acidosis)
Urine sample:
- Ketones (should be present with hypoglycemia unless hyperinsulinism)
- Organic acids (to screen for inborn errors of metabolism)
Key Diagnostic Patterns
Hyperinsulinism (Most Common Pathologic Cause):
- Inappropriately elevated insulin (>2 μU/mL) during hypoglycemia
- Suppressed ketones and free fatty acids
- High glucose infusion rate requirement (>8-10 mg/kg/min) to maintain euglycemia 2, 3
Hypopituitarism/Adrenal Insufficiency:
- Low cortisol (<5 μg/dL) and/or growth hormone during hypoglycemia
- May have associated midline defects or micropenis
Metabolic Disorders:
- Elevated lactate suggests glycogen storage disease
- Elevated ketones with hypoglycemia suggests fatty acid oxidation defects
- Abnormal organic acids on urine analysis
Confirmatory Testing
After initial critical sample:
If hyperinsulinism suspected:
- Genetic testing for KCNJ11, ABCC8, and other congenital hyperinsulinism genes 3
- Consider glucagon stimulation test (glucose rise >30 mg/dL suggests hyperinsulinism)
If endocrine disorder suspected:
- ACTH stimulation test for adrenal insufficiency
- Additional pituitary hormone evaluation
If metabolic disorder suspected:
- Expanded metabolic panel including acylcarnitine profile
- Specific enzyme assays based on initial findings
Clinical Context Matters
The workup intensity depends on severity and risk factors 4:
Transient hypoglycemia in at-risk infants (IDM, SGA, LGA, premature <37 weeks, birth weight <2500g or >4500g) typically resolves within 48-72 hours with feeding support and does not require extensive workup.
Persistent hypoglycemia requiring glucose infusion rates >8-10 mg/kg/min, lasting beyond 7 days, or occurring in a term appropriate-for-gestational-age infant with no risk factors mandates full diagnostic evaluation 5, 6.
Critical Pitfalls to Avoid
- Do not rely on point-of-care glucometers alone - they are inaccurate in neonates. Confirm all low readings with laboratory plasma glucose 4, 5
- Do not treat before obtaining critical sample - once glucose is corrected, diagnostic markers become uninterpretable
- Do not delay workup in severe cases - glucose requirements >12-15 mg/kg/min or failure to respond to standard management within 48 hours warrant immediate comprehensive evaluation 2
Management During Workup
- Maintain glucose >50 mg/dL (>2.8 mmol/L) with IV dextrose
- For suspected hyperinsulinism unresponsive to glucose alone, initiate diazoxide (5-15 mg/kg/day divided TID) as first-line pharmacotherapy
- If diazoxide fails, octreotide is second-line 2, 3
- Frequent glucose monitoring (every 1-3 hours initially)
The evidence base for neonatal hypoglycemia management remains limited with variable guideline quality 4, but the approach to persistent hypoglycemia is clear: obtain diagnostic samples during hypoglycemia before treatment, as this single step determines the entire diagnostic and therapeutic pathway 1.